Sem-P Prefilled Injection Pen 4Mg/3Ml

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1

PKR 12000.00

PKR 11400.00

You save: PKR 600.00

Quantity:

SKU: SEM_P_PREFILLED_INJECTION_PEN_4MG_3ML_NV

Category: Temp control medicines

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.

Purpose

Diabetes

Ingredients

Semaglutide

Warnings

Semaglutide is advised to not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Semaglutide is not a substitute for insulin. Diabetic ketoacidosis has been reported in insulin-dependent patients whom had rapid discontinuation or dose reduction of insulin when treatment with a GLP-1 receptor agonist is startedÂ .
Use of GLP-1 receptor agonists may be associated with gastrointestinal adverse reactions. This is advised to be considered when treating patients, with impaired renal function as nausea, vomiting, and diarrhoea may cause dehydration which could cause a deterioration of renal function .
Acute pancreatitis has been observed with the use of GLP-1 receptor agonists. Patients is advised to be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, semaglutide is advised to be discontinued; if confirmed, semaglutide is advised to not be restarted. Caution is advised to be exercised in patients with a history of pancreatitis.

Side Effects

Common: may affect up to 1 in 10 people : Complications of diabetic eye disease (retinopathy) â€“ you should inform your doctor if you experience eye problems, such as changes in vision, during treatment with this medicine. Uncommon: may affect up to 1 in 100 people : Inflamed pancreas (acute pancreatitis) which could cause severe pain in the stomach and back which does not go away. You should see a doctor immediately if you experience such symptoms. Rare: may affect up to 1 in 1,000 people : Severe allergic reactions (anaphylactic reactions, angioedema). You should seek immediate medical help and inform your doctor straight away if you get symptoms such as breathing problems, swelling of face, lips, tongue and/or throat with difficulty swallowing and a fast heartbeat .